Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature.

Thomas, Vinay Mathew; Abou-Ismail, Mouhamed Yazan; Lim, Ming Y

Thomas, Vinay Mathew; Abou-Ismail, Mouhamed Yazan; Lim, Ming Y.

Affiliation

Thomas VM; Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah, USA.
Abou-Ismail MY; Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah, USA.
Lim MY; Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah, USA.

Haemophilia ; 28(1): 4-17, 2022 Jan.

Article de En | MEDLINE | ID: mdl-34820989

Sujet(s)
Mots clés

acquired haemophilia A; emicizumab; haemostasis; von Willebrand disease

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladies de von Willebrand / Anticorps bispécifiques / Hémophilie A Type d'étude: Prognostic_studies / Systematic_reviews Limites: Humans Langue: En Journal: Haemophilia Sujet du journal: HEMATOLOGIA Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google